Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
World Health Organisation, 1990. Practical Chemotherapy of Malaria. World Health Organ Tech Rep Ser 805.
-
2
Sturchler D, Mittelholzer ML, Kerr L, 1993. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Saf 8 :160–168.
-
3
Muller O, van Hensbroek MB, Jaffar S, Drakeley C, Okorie C, Joof D, Pinder M, Greenwood B, 1996. A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria. Trop Med Int Health 1 :124–132.
-
4
Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M, 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. Am J Trop Med Hyg 31 :1–9.
-
5
Bojang KA, Schneider G, Forck S, Obaro SK, Jaffar S, Pinder M, Rowley J, Greenwood BM, 1998. A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg 92 :73–76.
-
6
Ertel W, Morrison MH, Ayala A, Chaudry IH, 1991. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 78 :1781–1788.
-
7
Landewe RB, Miltenburg AM, Breedveld FC, Daha MR, Dijkmans BA, 1992. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 19 :1353–1357.
-
8
Picot S, Peyron F, Donadille A, Vuillez JP, Barbe G, Ambroise-Thomas P, 1993. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 80 :127–133.
-
9
van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL, 1997. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mono-nuclear cells. J Rheumatol 24 :55–60.
-
10
Jeong JY, Jue DM, 1997. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 158 :4901–4907.
-
11
Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W, 1998. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 274 :R1058–R1064.
-
12
Hugosson E, Bjorkman A, Troye-Blomberg M, 2002. Chloroquine enhances the number of IL-10 producing cells and the expression of B7-2 and ICAM-1 in in vitro-cultured PBMC. Scand J Immunol 55 :399–408.
-
13
Brandts CH, Ndjave M, Graninger W, Kremsner PG, 1997. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet 350 :704–709.
-
14
Lell B, Sovric M, Schmid D, Luckner D, Herbich K, Long HY, Graninger W, Kremsner PG, 2001. Effect of antipyretic drugs in children with malaria. Clin Infect Dis 32 :838–841.
-
15
Tarimo DS, Minjas JN, Bygbjerg IC, 2002. Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy. Trop Med Int Health 7 :592–598.
-
16
Perlmann H, Helmby H, Hagstedt M, Carlson J, Larsson PH, Troye-Blomberg M, Perlmann P, 1994. IgE elevation and IgE anti-malarial antibodies in Plasmodium falciparum malaria: association of high IgE levels with cerebral malaria. Clin Exp Immunol 97 :284–292.
-
17
Ekvall H, Premji Z, Bjorkman A, 1998. Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: early treatment failure aggravates anaemia. Trans R Soc Trop Med Hyg 92: 556–560.
-
18
Ministry of Health T, 2000. Implementation of a new anti-malaria treatment policy in Tanzania: rationale for change and guide to the process of policy implementation, Task Force Report September 1999. Tanzania Health Res Bull 2 :10–13.
-
19
Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC, 1996. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 90 :179–181.
-
20
Rombo L, Bjorkman A, Sego E, Ericsson O, 1986. Whole blood concentrations of chloroquine and desethylchloroquine during and after treatment of adult patients infected with Plasmodium vivax, P. ovale or P. malariae. Trans R Soc Trop Med Hyg 80 :763–766.
-
21
Lell B, Brandts CH, Graninger W, Kremsner PG, 2000. The circadian rhythm of body temperature is preserved during malarial fever. Wien Klin Wochenschr 112 :1014–1015.
-
22
Ogle W, 1866. On the diurnal variations in the temperature of the human body in health. St. George′s Hosp Rep 1 :221–245.
-
23
Conroy RT, Mills JN, 1970. Human circadian rhythms. First edition. London: Churchill.
-
24
Gyhrs A, Pedersen BK, Bygbjerg I, Henrichsen J, Heron I, Petersen I, Skinhoj P, 1991. The effect of prophylaxis with chloroquine and proguanil on delayed-type hypersensitivity and antibody production following vaccination with diphtheria, tetanus, polio, and pneumococcal vaccines. Am J Trop Med Hyg 45 :613–618.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 680 | 598 | 145 |
| Full Text Views | 275 | 9 | 0 |
| PDF Downloads | 72 | 12 | 0 |
ANTIPYRETIC, PARASITOLOGIC, AND IMMUNOLOGIC EFFECTS OF COMBINING SULFADOXINE/PYRIMETHAMINE WITH CHLOROQUINE OR PARACETAMOL FOR TREATING UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA
ELISABETH HUGOSSON
ELISABETH HUGOSSON
Malaria Research Unit, Division of Infectious Diseases, and Clincial Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden; Department of Parasitology/Medical Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
Search for other papers by ELISABETH HUGOSSON in
Current site
Google Scholar
PubMed
Search for other papers by ELISABETH HUGOSSON in
Current site
Google Scholar
PubMed
DONATH TARIMO
DONATH TARIMO
Malaria Research Unit, Division of Infectious Diseases, and Clincial Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden; Department of Parasitology/Medical Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
Search for other papers by DONATH TARIMO in
Current site
Google Scholar
PubMed
Search for other papers by DONATH TARIMO in
Current site
Google Scholar
PubMed
MARITA TROYE-BLOMBERG
MARITA TROYE-BLOMBERG
Malaria Research Unit, Division of Infectious Diseases, and Clincial Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden; Department of Parasitology/Medical Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
Search for other papers by MARITA TROYE-BLOMBERG in
Current site
Google Scholar
PubMed
Search for other papers by MARITA TROYE-BLOMBERG in
Current site
Google Scholar
PubMed
SCOTT M. MONTGOMERY
SCOTT M. MONTGOMERY
Malaria Research Unit, Division of Infectious Diseases, and Clincial Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden; Department of Parasitology/Medical Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
Search for other papers by SCOTT M. MONTGOMERY in
Current site
Google Scholar
PubMed
Search for other papers by SCOTT M. MONTGOMERY in
Current site
Google Scholar
PubMed
ZUL PREMJI
ZUL PREMJI
Malaria Research Unit, Division of Infectious Diseases, and Clincial Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden; Department of Parasitology/Medical Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
Search for other papers by ZUL PREMJI in
Current site
Google Scholar
PubMed
Search for other papers by ZUL PREMJI in
Current site
Google Scholar
PubMed
ANDERS BJÖRKMAN
ANDERS BJÖRKMAN
Malaria Research Unit, Division of Infectious Diseases, and Clincial Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Stockholm University, Stockholm, Sweden; Department of Parasitology/Medical Entomology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
Search for other papers by ANDERS BJÖRKMAN in
Current site
Google Scholar
PubMed
Search for other papers by ANDERS BJÖRKMAN in
Current site
Google Scholar
PubMed
Sulfadoxine/pyrimethamine (SP) is increasingly used against malaria in sub-Saharan Africa because of chloroquine resistance. However, chloroquine may have a beneficial antipyretic effect. We therefore compared the combination of SP plus chloroquine, chloroquine alone, SP alone, and SP plus paracetamol in the treatment of uncomplicated Plasmodium falciparum malaria in 175 Tanzanian children (1–4 years old) in a randomized trial. Outcome variables were axillary temperatures every six hours, daily parasitemias, and serum levels of IgG antibodies to P. falciparum. Lower mean temperatures (6–48 hours) were achieved with SP plus chloroquine or paracetamol than with SP alone (P < 0.001) or chloroquine alone (P < 0.05). All three SP-treated groups showed high and similar parasite reduction (0–48 hours), whereas treatment with chloroquine alone was much less effective. Levels of IgG antibodies to P. falciparum increased significantly (P < 0.001) and similarly in the four treatment groups between days 0, 2. and 3. Thus, the addition of chloroquine or paracetamol to SP improved the clinical outcome, but did not affect the parasitologic response or antibody production.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
World Health Organisation, 1990. Practical Chemotherapy of Malaria. World Health Organ Tech Rep Ser 805.
-
2
Sturchler D, Mittelholzer ML, Kerr L, 1993. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Saf 8 :160–168.
-
3
Muller O, van Hensbroek MB, Jaffar S, Drakeley C, Okorie C, Joof D, Pinder M, Greenwood B, 1996. A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria. Trop Med Int Health 1 :124–132.
-
4
Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M, 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. Am J Trop Med Hyg 31 :1–9.
-
5
Bojang KA, Schneider G, Forck S, Obaro SK, Jaffar S, Pinder M, Rowley J, Greenwood BM, 1998. A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg 92 :73–76.
-
6
Ertel W, Morrison MH, Ayala A, Chaudry IH, 1991. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 78 :1781–1788.
-
7
Landewe RB, Miltenburg AM, Breedveld FC, Daha MR, Dijkmans BA, 1992. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 19 :1353–1357.
-
8
Picot S, Peyron F, Donadille A, Vuillez JP, Barbe G, Ambroise-Thomas P, 1993. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 80 :127–133.
-
9
van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL, 1997. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mono-nuclear cells. J Rheumatol 24 :55–60.
-
10
Jeong JY, Jue DM, 1997. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 158 :4901–4907.
-
11
Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W, 1998. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 274 :R1058–R1064.
-
12
Hugosson E, Bjorkman A, Troye-Blomberg M, 2002. Chloroquine enhances the number of IL-10 producing cells and the expression of B7-2 and ICAM-1 in in vitro-cultured PBMC. Scand J Immunol 55 :399–408.
-
13
Brandts CH, Ndjave M, Graninger W, Kremsner PG, 1997. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet 350 :704–709.
-
14
Lell B, Sovric M, Schmid D, Luckner D, Herbich K, Long HY, Graninger W, Kremsner PG, 2001. Effect of antipyretic drugs in children with malaria. Clin Infect Dis 32 :838–841.
-
15
Tarimo DS, Minjas JN, Bygbjerg IC, 2002. Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy. Trop Med Int Health 7 :592–598.
-
16
Perlmann H, Helmby H, Hagstedt M, Carlson J, Larsson PH, Troye-Blomberg M, Perlmann P, 1994. IgE elevation and IgE anti-malarial antibodies in Plasmodium falciparum malaria: association of high IgE levels with cerebral malaria. Clin Exp Immunol 97 :284–292.
-
17
Ekvall H, Premji Z, Bjorkman A, 1998. Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: early treatment failure aggravates anaemia. Trans R Soc Trop Med Hyg 92: 556–560.
-
18
Ministry of Health T, 2000. Implementation of a new anti-malaria treatment policy in Tanzania: rationale for change and guide to the process of policy implementation, Task Force Report September 1999. Tanzania Health Res Bull 2 :10–13.
-
19
Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC, 1996. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 90 :179–181.
-
20
Rombo L, Bjorkman A, Sego E, Ericsson O, 1986. Whole blood concentrations of chloroquine and desethylchloroquine during and after treatment of adult patients infected with Plasmodium vivax, P. ovale or P. malariae. Trans R Soc Trop Med Hyg 80 :763–766.
-
21
Lell B, Brandts CH, Graninger W, Kremsner PG, 2000. The circadian rhythm of body temperature is preserved during malarial fever. Wien Klin Wochenschr 112 :1014–1015.
-
22
Ogle W, 1866. On the diurnal variations in the temperature of the human body in health. St. George′s Hosp Rep 1 :221–245.
-
23
Conroy RT, Mills JN, 1970. Human circadian rhythms. First edition. London: Churchill.
-
24
Gyhrs A, Pedersen BK, Bygbjerg I, Henrichsen J, Heron I, Petersen I, Skinhoj P, 1991. The effect of prophylaxis with chloroquine and proguanil on delayed-type hypersensitivity and antibody production following vaccination with diphtheria, tetanus, polio, and pneumococcal vaccines. Am J Trop Med Hyg 45 :613–618.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 680 | 598 | 145 |
| Full Text Views | 275 | 9 | 0 |
| PDF Downloads | 72 | 12 | 0 |